MyFinsight
Home
Blog
About
Net proceeds from
issuance of common...
$194,580K
Issuance of shares
through employee stock...
$1,520K
(22.88%↑ Y/Y)
Proceeds from options
exercised
$16K
Net cash provided by
financing activities
$196,116K
(1238.49%↑ Y/Y)
Net decrease in
cash, cash...
-$28,569K
(12.53%↑ Y/Y)
Canceled cashflow
$196,116K
Sales and maturities
of marketable...
$80,540K
(-76.38%↓ Y/Y)
Proceeds from sale of
property and equipment
$90K
Stock-based compensation
$18,075K
(-58.80%↓ Y/Y)
Operating lease
right-of-use assets
-$9,507K
(41.14%↑ Y/Y)
Accrued expenses
$6,356K
(146.79%↑ Y/Y)
Depreciation and
amortization
$2,082K
(-58.13%↓ Y/Y)
Accounts receivable
-$1,810K
(-163.82%↓ Y/Y)
Other assets
-$612K
(-102.51%↓ Y/Y)
Loss on disposal of
property and equipment
-$153K
Net cash (used in)
provided by investing...
-$141,572K
(-170.35%↓ Y/Y)
Canceled cashflow
$80,630K
Net cash used in
operating activities
-$83,113K
(66.56%↑ Y/Y)
Canceled cashflow
$38,595K
Collaboration revenue
$7,659K
Interest income
$5,797K
Other segment
information
-$329K
Purchases of marketable
securities
$220,393K
(58.77%↑ Y/Y)
Purchases of property and
equipment
$1,809K
(85.73%↑ Y/Y)
Net loss
-$106,634K
(50.54%↑ Y/Y)
Canceled cashflow
$13,785K
Accounts payable
-$7,086K
(-59.92%↓ Y/Y)
Operating lease
liabilities
-$4,996K
(89.07%↑ Y/Y)
Prepaid expenses and
other current assets
$1,419K
(126.41%↑ Y/Y)
Deferred revenue
-$630K
(93.17%↑ Y/Y)
Accretion of investment
discounts
$614K
(-84.44%↓ Y/Y)
Change in fair value of
investments, net
$329K
(141.86%↑ Y/Y)
Research and development
$82,595K
General and
administrative
$37,824K
Back
Back
Cash Flow
Intellia Therapeutics, Inc. (NTLA)
Intellia Therapeutics, Inc. (NTLA)
source: myfinsight.com